ANIP — ANI PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1023024 ·
Last close
$79.24
Market Cap
$1.80B
52W High
$87.76
52W Low
$73.54
ADV30
307,854
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 237,462,000 | 143,880,000 | 38,706,000 | 29,492,000 | 1,421,970,000 | 311,176,000 | 859,670,000 |
| Dec 2025 | 247,060,000 | 146,791,000 | 29,127,000 | 27,490,000 | 1,440,377,000 | 285,585,000 | 899,653,000 |
| Sep 2025 | 227,813,000 | 134,424,000 | 22,832,000 | 26,617,000 | 1,408,152,000 | 262,610,000 | 902,335,000 |
| Jun 2025 | 211,371,000 | 136,756,000 | 15,169,000 | 8,549,000 | 1,343,001,000 | 217,797,000 | 881,394,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$185,225,000
Investing CF
$-34,321,000
Financing CF
$-9,944,000
CapEx
$-34,321,000
Dividends Paid
$-1,157,000
Buybacks
$-10,003,000
EPS Diluted TTM
$3.36
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-23,099,000
Inventory
$143,067,000
Receivables
$281,082,000
ST Investments
$9,131,000
EBIT TTM
$115,851,000
Pretax Income TTM
$95,791,000
Interest Exp TTM
$20,060,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$923,705,984
EBITDA
$197,379,008
Free Cash Flow
$140,259,504
Enterprise Value
$2,009,636,480
Total Cash
$326,060,992
Total Debt
$630,209,984
Shares Out
22,734,618
Trailing EPS
$3.91
Book Value
$26.34
ROE
18.3%
ROA
5.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 883,366,000 | 81,230,000 | 78,337,000 | 1,440,377,000 | 899,653,000 | — | 185,225,000 |
| Dec 2024 | 614,376,000 | 2,218,000 | -18,522,000 | 1,284,469,000 | 855,939,000 | — | 64,017,000 |
| Dec 2023 | 486,816,000 | 49,529,000 | 18,779,000 | 904,422,000 | 446,823,000 | — | 118,959,000 |
| Dec 2022 | 316,385,000 | -25,734,000 | -47,896,000 | 760,087,000 | 421,547,000 | — | -31,203,000 |
TTM Snapshot
Revenues TTM
$416,043,000
NetIncome TTM
$-27,273,000
OpCashFlow TTM
$0
Assets (Latest)
$1,283,697,000
Forward EPS
$10.76
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | $1.80B | $28.86 | — |
| GENB | Generate Biomedicines, Inc. | $1.79B | $14.00 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.79B | $8.17 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.79B | $30.02 | — |
| DMRA | Damora Therapeutics, Inc. | $1.78B | $28.99 | — |
News headlines (Yahoo Finance, 1h cache)
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
2026-07-31 14:00 · Yahoo
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
2026-07-31 12:10 · Yahoo
The Bull Case For ANI Pharmaceuticals (ANIP) Could Change Following Positive ILUVIEN Phase 4 NIU-PS Data
2026-07-25 17:09 · Yahoo
Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results?
2026-07-25 04:19 · Yahoo
2 Reasons to Watch ANIP and 1 to Stay Cautious
2026-07-24 20:01 · Yahoo
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
2026-07-24 13:05 · Yahoo
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
2026-07-24 10:50 · Yahoo
2 Small-Cap Stocks Worth Investigating and 1 We Brush Off
2026-07-21 09:02 · Yahoo
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
2026-07-16 20:34 · Yahoo
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chroni
2026-07-13 10:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.